Anja Goldenbæk, MSc, is Director, Nonclinical Development at Hemab. She is a European Registered Toxicologist (ERT) and brings more than two decades of experience in non-clinical safety within the pharmaceutical industry with  extensive expertise in planning, monitoring, and interpreting nonclinical studies, ensuring the safety of pharmaceutical candidates from early research through life cycle management. Her expertise spans several modalities, including small molecules, peptides, proteins, monoclonal and bispecific antibodies. Most recently, Anja served as Associate Director at Genmab, with previous experience at Ferring and Novo Nordisk. She holds a Master of Science in Biology from the University of Copenhagen and in Applied  Toxicology from the University of Surrey.